gms | German Medical Science

Deutscher Rheumatologiekongress 2021, 49. Kongress der Deutschen Gesellschaft für Rheumatologie (DGRh), 35. Jahrestagung der Deutschen Gesellschaft für Orthopädische Rheumatologie (DGORh), Wissenschaftliche Herbsttagung der Gesellschaft für Kinder- und Jugendrheumatologie (GKJR)

15.09. - 18.09.2021, virtuell

Article

Send article

Assessment of clinical and anti-destructive effect of anti-β-cell therapy depending on combination with conventional synthetic disease-modifying Antirheumatic drugs or glucocorticoids in patients with rheumatoid arthritis

Meeting Abstract

Search Medline for

  • Anastasia Kudryavtseva - V.A. Nasonova Research Institute of Rheumatology, Moscow
  • Galina Lukina - V.A. Nasonova Research Institute of Rheumatology, Moscow
  • Eugenia Aronova - V.A. Nasonova Research Institute of Rheumatology, Moscow
  • Galina Gridneva - V.A. Nasonova Research Institute of Rheumatology, Moscow
  • Svetlana Glukhova - V.A. Nasonova Research Institute of Rheumatology, Moscow
  • Aleksander Smirnov - V.A. Nasonova Research Institute of Rheumatology, Moscow

Deutsche Gesellschaft für Rheumatologie. Deutsche Gesellschaft für Orthopädische Rheumatologie. Gesellschaft für Kinder- und Jugendrheumatologie. Deutscher Rheumatologiekongress 2021, 49. Kongress der Deutschen Gesellschaft für Rheumatologie (DGRh), 35. Jahrestagung der Deutschen Gesellschaft für Orthopädische Rheumatologie (DGORh), Wissenschaftliche Herbsttagung der Gesellschaft für Kinder- und Jugendrheumatologie (GKJR). sine loco [digital], 15.-18.09.2021. Düsseldorf: German Medical Science GMS Publishing House; 2021. DocRA.53

doi: 10.3205/21dgrh134, urn:nbn:de:0183-21dgrh1348

Published: September 14, 2021

© 2021 Kudryavtseva et al.
This is an Open Access article distributed under the terms of the Creative Commons Attribution 4.0 License. See license information at http://creativecommons.org/licenses/by/4.0/.

Outline

Text

Objective: To evaluate the effectiveness and anti-destructive effect of anti-B-cell therapy (rituximab) in various combinations (RTM-mono, RTM + DMARD, RTM + GK) in patients with rheumatoid arthritis in real clinical practice.

Methods: Clinical and radiological evaluation of 110 patients with rheumatoid arthritis who received rituximab therapy (RTM) as monotherapy (group 1), in combination with methotrexate (group 2), leflunomide (group 3), and group 4 with other basic anti-inflammatory drugs. The same110 patients with rheumatoid arthritis were divided into 2 groups depending on the presence of concomitant glucocorticoid therapy

Results: When assessing at 48 weeks of treatment with these regimens, the achievement of remission and a low degree of activity was observed in 22.36% of patients. An X-ray evaluation showed the absence of progression in the total score in 60.9%. When assessing progression in the monotherapy group, there was no progression in 76.92%, in the group of PTM + MT - in 54.29%, in the group of PTM + LEF - 65.0%, in the group of other DMARDs - 50% of patients. When assessing the clinical effect in the group receiving GK - remission and a low degree of activity - 19.67% of patients, in the group without GK - 21.05%. Assessing the radiological dynamics, it was shown that in the group not receiving GK - inhibition by the total score occurred in 54.55%, receiving - 61.54%.

Conclusion: This work has demonstrated the high therapeutic efficacy of RTM in real clinical practice. There were no significant differences in the degree of progression depending on the concomitant therapy of DMARDs or GK. In the treatment of RTM, inhibition of articular destruction is possible even against the background of clinical deterioration

Disclosures: None declared